LifeCycle sells North American royalties for Fenoglide

08/21/2008 | Reuters

LifeCycle Pharma, a Danish biotech company, has sold the North American royalty stream from its drug Fenoglide to Cowen Healthcare Royalty Partners in a deal worth as much as $105 million. Fenoglide, a cholesterol-lowering treatment, entered the U.S. market this year through Sciele Pharma.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
Bridgewater, NJ